ClinicalTrials.gg
CompletedNCT07466940Updated Apr 6, 2026

A Clinical Study to Evaluate SM17 in Healthy Participants

A Phase 1 interventional study of SM17 and SM17 placebo in Atopic Dermatitis, Asthma and Inflammatory Bowel Disease, sponsored by SinoMab BioScience Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by SinoMab BioScience Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
168th of 190
30 · median 164
Started
2025
with 33 others
Phase 1
38 of 206
14 open now
Registered
183rd of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 168th largest by enrollment of the 190 interventional ones that give a count, is one of 34 that started in 2025, is one of 38 in phase 1, and was the 183rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants. It also aims to evaluate the bioavailability of SM17 SC compared to SM17 IV.

Read the detailed description

This Phase I study will be conducted in Chinese healthy adult participants to evaluate the safety, tolerability, PK, and immunogenicity of SM17 SC. This study plans to enroll a total of 30 healthy participants across 4 cohorts, among which three cohorts (n = 8 per cohort) will receive SM17 via subcutaneous injection (SC cohorts), and one cohort (n = 6) will receive SM17 via intravenous injection (IV cohort).

SM17 SC cohorts:

This part is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. A total of 24 healthy participants will be enrolled into three SC cohorts (A1 to A3), with dose levels of 195 mg, 390 mg, and 780 mg, respectively. Each cohort will enroll 8 healthy participants. Each participant will receive a single SC dose of either SM17 (n = 6) or placebo (n = 2).

SM17 IV cohort:

This part is an open-label, single-dose study. Six healthy participants will be enrolled in a single IV cohort (Cohort B) and will each receive a single intravenous injection of SM17 at a dose of 390 mg.

The SM17 SC A2 cohort and SM17 IV cohort (Cohort B) will be enrolled in parallel, and participants will be randomized to one of the two cohorts.

A dedicated Safety Review Committee (SRC) will be established for this study. The SRC is responsible for deciding whether to proceed to the next dose cohort based on a review of all relevant safety data from participants at the current dose level for at least 7 days after dosing.

03

Conditions studied

  • Atopic Dermatitis
  • Asthma
  • Inflammatory Bowel Disease

Keywords

  • AD
  • IL-17RB
  • IL-25 receptor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing to sign the ICF, and be able to complete clinical visits and study-related procedures.
  2. Aged 18-55 years (both inclusive) at the time of signing the ICF, regardless of sex.
  3. (BMI) ≥ 18.5 and \< 28.0 kg/m2, and body weight ≥ 50 kg (for males) and ≥ 45 kg (for females) at screening.
  4. Normal or abnormal but clinically insignificant findings in medical history and inquiries, vital signs, physical examination, laboratory tests (hematology, clinical chemistry, urinalysis, and coagulation tests), immunoglobulins, 12-lead , and non-contrast chest CT at screening.
  5. Fertile men and women of must consent to use one of the highly effective methods specified in Appendix 1 of the protocol from signing the ICF to 6 months after dosing, and have no plan to donate sperm or egg cells during this period.

Exclusion criteria

Exclusion Criteria:

  1. Frequent alcohol consumption within 6 months prior to the screening visit, defined as an average weekly intake of > 14 units of alcohol (1 unit of alcohol ≈ 360 mL of beer, 45 mL of spirit with the alcohol content of 40%, or 150 mL of wine), inability to abstain from alcohol from the screening visit or within 48 h pre-dose until the end of study (EOS), or a positive breath alcohol test at baseline.
  2. Current or history of diseases deemed by the investigator to be clinically significant or likely to interfere with the study, including but not limited to diseases related to the neurological, cardiovascular, respiratory, hematological, endocrine, genitourinary, gastrointestinal, musculoskeletal systems, etc.
  3. Planned major surgery during the study, major surgery within 4 weeks prior to dosing, or surgical history deemed clinically significant by the investigator.
  4. Smoking history (> 5 cigarettes per day on average) within 3 months prior to the screening visit, or inability to abstain from any tobacco products during the study.
  5. PR interval > 210 ms on 12-lead or corrected for heart rate using Fridericia's formula (QTcF; see Appendix 3): QTcF ≥ 450 ms for males and QTcF ≥ 470 ms for females.
  6. Abnormal laboratory parameter values as follows: a) total > 1.5 × (ULN); b) or aspartate aminotransferase > 1.5 × ULN; c) serum creatinine > ULN; d) white blood cell count below the lower limit of normal (LLN); or other abnormalities deemed by the investigator to be clinically significant, rendering the participant ineligible for enrollment.
  7. Recent infections (including chronic or localized infections) within 7 days prior to the screening visit, or presence of recurrent infections that, as assessed by the investigator, may affect the interpretation of trial results.
  8. Received a vaccine within 1 month prior to dosing.
  9. History of any within 5 years prior to the screening visit.
  10. History of known primary or secondary immunodeficiency disorders.
  11. History of drug abuse prior to dosing, or positive urine drug abuse screening at baseline.
  12. Known allergic reactions to monoclonal antibody components or , or a history of suspected reactions to the study drug or any components thereof as judged by the investigator.
  13. Positive screen test for -Ab, , -Ab, or TP-Ab at screening;
  14. Received any prescription drugs, over-the-counter (OTC) drugs, biological products, dietary supplements, or Chinese herbal medicines within 14 days prior to dosing or 5 half-lives (whichever is longer); participated in another clinical trial involving an drug/device and received investigational treatment within 3 months prior to dosing or 5 half-lives (whichever is longer); or participated in 3 or more clinical trials of drugs/devices and received investigational treatment within the past year.
  15. Presence of tattoos, scars, or any other conditions at or near the injection site that, in the investigator's opinion, may interfere with injection site assessment.
  16. Blood (including blood products) donation or blood loss ≥ 500 mL due to surgery or trauma within 2 months prior to the screening visit; donation of hematopoietic stem cells or bone marrow within 3 months prior to dosing, or planned donation of blood, bone marrow, or hematopoietic stem cells during the study.
  17. History of trypanophobia or hemophobia, or cannot tolerate intravenous cannulation.
  18. Pregnant or lactating women, or a positive pregnancy test (for females).
  19. Any other conditions that, in the investigator's opinion, render the participant ineligible for the study.
  20. Participants who may be unable to complete the study for any other reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SM17 SC Cohort 1

    single ascending dose cohort A1, participants will receive Dose 1 of SM17 or placebo subcutaneously with randomization ratio 3:1

    Biological: SM17 · Drug: SM17 placebo

  • Experimental
    SM17 SC Cohort22

    single ascending dose cohort A2, participants will receive Dose2 of SM17 or placebo subcutaneously with randomization ratio 3:1

    Biological: SM17 · Drug: SM17 placebo

  • Experimental
    SM17 IV Cohort

    This is an open-label, single dose cohort B, participants will receive Dose2 of SM17 intravenously in this cohort. The SM17 SC A2 cohort and SM17 IV cohort (Cohort B) will be enrolled in parallel, and participants will be randomized 8:6 to one of the two cohorts.

    Biological: SM17

  • Experimental
    SM17 SC Cohort 3

    single ascending dose cohort A3, participants will receive 780mg of SM17 or placebo subcutaneously in this cohort with randomization ratio 3:1

    Biological: SM17 · Drug: SM17 placebo

Interventions

  • BiologicalSM17

    SM17 monoclonal antibody

  • DrugSM17 placebo

    placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent AEs

    To evaluate the safety and tolerability of SM17 in Chinese healthy volunteers administrated with single dose of SM17 or placebo intravenously. Treatment emergent AE was any unfavorable or unintended medical occurrence in each subject, including any abnormal changes in vital signs or lab testing with clinical significance judged by investigators, that happened during the period of receiving or after receiving the investigational product, categorized by type, severity, and causality with the study drug

    Time frame: Day 0 to Day 85

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    To evaluate the PK parameter(AUC), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  2. Peak Plasma Concentration (Cmax)

    To evaluate the PK parameter(Cmax), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  3. Time to peak (Tmax)

    To evaluate the PK parameter(Tmax), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  4. Elimination half-life (T1/2)

    To evaluate the PK parameter(T 1/2), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  5. Elimination Rate Constant (Kel)

    To evaluate the PK parameter(Kel), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  6. Total drug clearance from plasma (CL)

    To evaluate the PK parameter(CL), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  7. Apparent volume of distribution at steady state after extravascular administration (Vz)

    To evaluate the PK parameter(Vz), which calculated from serum SM17 concentration, of a single dose of SM17 in healthy Chinese adult participants.

    Time frame: Day1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 43, 57, 85(Cohort A1, Cohort A2, Cohort A3); Day1, 2, 3, 4, 6, 8, 15, 29, 43, 57, 85(Cohort B).

  8. Immunogenicity

    To evaluate the immunogenicity of SM17 in adult healthy participants. Incidence of treatment emergent anti-drug antibodies (ADAs) during the study.

    Time frame: Day1, 15, 29, 85

07

Study locations

1 site
  • PKUCare Luzhong Hospital
    Zibo, Shandong, China
08

References and documents

Individual participant data

Plan to share: Yes — Protocol, TFL, CSR and related documents

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Feb 2026, 3 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 3 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 12, 2026
StartActual
Oct 14, 2025
Primary completionActual
Feb 3, 2026
CompletionActual
Feb 3, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07466940
Lead sponsor
SinoMab BioScience Ltd
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Oct 14, 2025
Primary completion
Feb 3, 2026
Completion
Feb 3, 2026
Last update
Apr 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion